Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
May 22, 2017 • 9:00 AM EDT
Ligand to Participate in Two Upcoming Investor Conferences
May 9, 2017 • 4:01 PM EDT
Ligand Reports First Quarter 2017 Financial Results
Apr 13, 2017 • 9:00 AM EDT
Ligand to Report First Quarter 2017 Results on May 9th
May 9, 2017 • 4:30pm EDT
See all events
Mar 14, 2017 • 4:30pm EDT
The Ritz-Carlton, Laguna Niguel, Dana Point, CA
Feb 28, 2017 • 10:00am EDT
New York, NY
May 31, 2017
Jun 8, 2017 • 4:00pm EDT
Ono highlights Ligand’s OmniAb technology in May 2017 Progress Update for Discovery & Research https://t.co/dsMCsJEsnw
Captisol-enabled ADX-102 Phase 2 data presented at annual meeting of Assoc. for Research in Vision and Ophthalmology https://t.co/wJ474b7F7X
Captisol-enabled programs pevonedistat and TAK-20 both highlighted by Takeda during FY2016 call https://t.co/9i4R8VC7eH